Clinical Research Directory
Browse clinical research sites, groups, and studies.
Efficacy of Lactobacillus Paracasei LC19 on Type 2 Diabetes
Sponsor: Beijing Chao Yang Hospital
Summary
This is a randomized, double-blind, placebo-controlled clinical trial. The objective of this trial is to determine whether Lactobacillus paracasei LC19 supplementation has a positive effect on glucose lowering in patients with type 2 diabetes (T2D).
Official title: Efficacy of Lactobacillus Paracasei LC19 on Newly Diagnosed Type 2 Diabetes
Key Details
Gender
All
Age Range
18 Years - 65 Years
Study Type
INTERVENTIONAL
Enrollment
60
Start Date
2024-10-12
Completion Date
2026-12-31
Last Updated
2025-02-07
Healthy Volunteers
No
Conditions
Interventions
Lactobacillus paracasei LC19 supplementation
Orally administered Lactobacillus paracasei LC19 strain product, in addition to lifestyle intervention. This product is a probiotic milk powder, and the Lactobacillus paracasei LC19 strain is capable of producing high levels of tryptophan-conjugated cholic acid (Trp-CA)( 25g/packet, 2 packets/day).
Placebo probiotic milk powder
Orally administered placebo probiotic milk powder, in addition to lifestyle intervention. The placebo probiotic strain also belongs to Lactobacillus paracasei species, but does not produce Trp-CA. These products have the same color, odor, appearance, and packaging (25g/packet, 2 packets/day).
Locations (1)
Beijing Chao-yang Hospital, Capital Medical University
Beijing, Beijing Municipality, China